Macrolides in the treatment of bronchiolitis obliterans in allograft recipients

Bone Marrow Transplantation

Volumn 44, Issue 2, 2009, Pages 69-73

  Maimon, N ^a   Lipton, J H ^b   Chan, C K N ^a   Marras, T K ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; CORTICOSTEROID; MACROLIDE; ROXITHROMYCIN; STEROID; TROLEANDOMYCIN;

ANTIBIOTIC THERAPY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BRONCHIOLITIS OBLITERANS; CLINICAL TRIAL; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG EFFICACY; FORCED EXPIRATORY VOLUME; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOMODULATION; LOW DRUG DOSE; OPEN LUNG BIOPSY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SURVIVAL RATE; TRANSBRONCHIAL BIOPSY; TREATMENT DURATION; TREATMENT RESPONSE;

ANTI-BACTERIAL AGENTS; BRONCHIOLITIS OBLITERANS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOLOGIC FACTORS; MACROLIDES; TRANSPLANTATION, HOMOLOGOUS;

EID: 68149089659     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.106     Document Type: Review

References (33)

1. Chan CK, Hyland RH, Hutcheon MA. Pulmonary complications following bone marrow transplantation. Clin Chest Med 1990; 11: 323-332.
2. Chan CK, Hyland RH, Hutcheon MA, Minden MD, Alexander MA. Small-airways disease in recipients of allogeneic bone marrow transplants. An analysis of 11 cases and a review of the literature. Medicine (Baltimore) 1987; 66: 327-340.
3. Bryant D. Pulmonary complications. 2004 In: Atkinson K, Champlin R, Ritz J, Fibbe WE, Ljungman P, Brenner MK, (eds) Clinical Bone Marrow and Blood Stem Cell Transplantation, 3rd edn. Cambridge, Cambridge University Press, pp 1466.
4. Marras T, Chan C. Obliterative bronchiolitis complicating bone marrow transplantation. Semin Respir Crit Care Med 2003; 24: 531-541.
5. Afessa B, Litzow MR, Tefferi A. Bronchiolitis obliterans and other late onset non infectious pulmonary complications in hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 28: 425-431.
6. Cooke KR, Krenger W, Hill G, Martin TR, Kobzik L, Brewer J et al. Host reactive donor T-cells are associated with lung injury after experimental allogeneic bone marrow transplantation. Blood 1998; 92: 2571-2580.
7. Krebs R, Tikkanen JM, Nykanen AI, Krebs R, Tikkanen JM, Nykänen AI et al. Dual role of vascular endothelial growth factor in experimental obliterative bronchiolitis. Transplantation 2004; 78: 541-544.
8. Ratanatharathorn V, Ayash L, Lazarus HM, Fu J, Uberti JP. Chronic graft-versus-host disease: Clinical manifestations and therapy. Bone Marrow Transplant 2001; 28: 121-129.
9. Egan J. Obliterative bronchiolitis after lung transplantation. Am J Respir Crit Care Med 2004; 170: 931-932.
10. Khalid M, Al Saghir A, Saleemi S, Al Dammas S, Zeitouni M, Al Mobeireek A et al. Azithromycin in bronchiolitis obliterans complicating bone marrow transplantation: A preliminary study. Eur Respir J 2005; 25: 490-493.
11. Verleden GM, DuPont LJ. Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2004; 77: 1465-1467.
12. Kurdowska A, Noble JM, Griffith DE. The effects of azithromycin and clarithromycin on ex vivo interleukin-8 (IL-8) release from whole blood and IL-8 production by human alveolar macrophages. J Antimicrob Chemother 2001; 47: 867-870.
13. Koch CC, Esteban DJ, Chin AC, Olson ME, Read RR, Ceri H et al. Apoptosis, oxidative metabolism and interleuken-8 production in human neutrophils exposed to azithromycin: Effects of Streptoccus pneumoniae. J Antimicrob Chemother 2000; 46: 19-26.
14. Milojkovic D, Mufti JG. Extending the role of allogenic stem cell transplantation. Lancet 2001; 357: 652-654.
15. Kotloff RM, Ahya VN, Crawford SW. Pulmonary complications of solid organ and hematopoietic stem cell transplantation. Am J Respir Crit Care Med 2004; 170: 22-48.
16. Beinert T, Dull T, Wolf K, Behr J, Kolb H. Late pulmonary impairment following allogeneic bone marrow transplantation. Eur J Med Res 1996; 1: 343-348.
17. Chien JW, Martin PJ, Gooley TA, Nichols WG, Clark JG. Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. Am J Respir Crit Care Med 2003; 168: 146-147.
18. Nagai H, Shishido H, Yoneda R, Yamaguchi E, Tamura A, Kurashima A. Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis. Respiration 1991; 58: 145-149.
19. Rubin BK, Druce H, Ramirez OE, Palmer R. Effect of clarithromycin on nasal mucus properties in healthy subjects and in patients with purulent rhinitis. Am J Respir Crit Care Med 1997; 155: 2018-2023.
20. Koh YY, Lee MH, Sun YH, Sung KW, Chae JH. Effect of roxithromycin on airway responsiveness in children with bronchiectasis: A double-blind, placebo-controlled study. Eur Respir J 1997; 10: 994-999.
21. Jaffe A, Francis J, Rosenthal M, Bush A. Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet 1998; 351: 420.
22. Spector S, Katz F, Farr R. Troleandomycin: Effectiveness in steroid-dependent asthma and bronchitis. J Allergy Clin Immunol 1974; 54: 367-379.
23. Ordonez CL, Stulbarg M, Grundland H. Effect of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: A pilot study. Pediatr Pulmonol 2001; 32: 29-37.
24. Koch CC, Esteban DJ, Chin AC, Ceri H. Apoptosis, oxidative metabolism and interleuken-8 production in human neutrophils exposed to azithromycin: Effects of Streptoccus pneumoniae. J Antimicrob Chemother 2000; 46: 19-26.
25. Ianaro A, Ialenti A, Maffa P, Sautebin L, Rombolà L, Carnuccio R. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther 2000; 292: 156-163.
26. Culic O, Erakovic V, Cepelak I, Barisić K, Brajsa K, Ferencić Z. Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur J Pharmacol 2002; 450 277-289.
27. Culic O, Erakovic V, Parnham MJ. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol 2001; 429: 209-229.
28. Siracusa A, Brugnami G, Fiordi T, Areni S, Severini C, Marabini A. Troleandomycin in the treatment of difficult asthma. J Allergy Clin Immunol 1993; 92: 677-682.
29. Simpson JL, Powell H, Boyle MJ. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med 2008; 177: 148-155.
30. Ball BD, Hill MR, Brenner M. Effect of low-dose troleandomycin on glucocorticoid pharmacokinetics and airway hyper-responsiveness in severely asthmatic children. Ann Allergy 1990; 65: 37-45.
31. Tamaoki J, Takeyama K, Tagaya E, Konno K. Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory tract infections. Antimicrob Agents Chemother 1995; 39: 1688-1690.
32. Shimizu T, Shimizu S, Hattori R Gabazza EC, Majima Y. In vivo and in vitro effects of macrolide antibiotics on mucus secretion in airway epithelial cells. Am J Respir Crit Care Med 2003; 168 581-587.
33. Gerhardt SG, McDyer JF, Girgis RE, Orens JB. Maintenance azithromycin therapy for bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2003; 168: 121-125.